A Phase II/III, Multicenter, Randomized, Open Label, Active Controlled, Clinical Study to Assess the Immunogenicity and Safety of Tetanus Toxoid, Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine Manufactured by Serum Institute of India Pvt. Ltd (SIIPL) in Comparison with Boostrix Vaccine of GSK in Healthy Adults, Adolescents and Children in India
Latest Information Update: 13 Nov 2018
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Serum Institute of India
Most Recent Events
- 13 Nov 2018 New trial record